Sight Sciences, Inc. (SGHT)
NASDAQ: SGHT · Real-Time Price · USD
4.660
-0.550 (-10.56%)
Nov 4, 2024, 4:00 PM EST - Market closed
Sight Sciences Employees
Sight Sciences had 214 employees as of December 31, 2023. The number of employees decreased by 36 or -14.40% compared to the previous year.
Employees
214
Change (1Y)
-36
Growth (1Y)
-14.40%
Revenue / Employee
$371,005
Profits / Employee
-$244,491
Market Cap
234.43M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 214 | -36 | -14.40% |
| Dec 31, 2022 | 250 | 38 | 17.92% |
| Dec 31, 2021 | 212 | 43 | 25.44% |
| Dec 31, 2020 | 169 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Accolade | 2,400 |
| AVITA Medical | 207 |
| TScan Therapeutics | 154 |
| Rigel Pharmaceuticals | 147 |
| Heron Therapeutics | 126 |
| Lexeo Therapeutics | 58 |
| Sera Prognostics | 57 |
| Artiva Biotherapeutics | 43 |
SGHT News
- 18 days ago - Sight Sciences to Report Third Quarter Financial Results on November 7, 2024 - GlobeNewsWire
- 21 days ago - Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial - GlobeNewsWire
- 2 months ago - Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Sight Sciences, Inc. (SGHT) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Sight Sciences to Report Second Quarter Financial Results on August 1, 2024 - GlobeNewsWire
- 5 months ago - Sight Sciences Announces the Release of its First Sustainability Report - GlobeNewsWire
- 5 months ago - Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis - GlobeNewsWire
- 5 months ago - Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma - GlobeNewsWire